Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
15 December 2023

Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data

Authors: Julia Pisc, Angela Ting [email protected], Michelle Skornicki, Omar Sinno, and Edward LeeAuthor Info & Affiliations
Volume 13, Number 1
https://doi.org/10.57264/cer-2023-0108
PDFFormats

Abstract

Aim: There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM® MarketScan® database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period. Results: Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MG-related healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations. Conclusion: Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.

Supplementary Material

File (supplementary data.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat. Rev. Dis. Primers 5(1), 30 (2019).
PubMed
Google Scholar
2.
Juel VC, Massey JM. Myasthenia gravis. Orphanet J. Rare Dis. 2, 44 (2007).
PubMed
Google Scholar
3.
Melzer N, Ruck T, Fuhr P et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J. Neurol. 263(8), 1473–1494 (2016).
PubMed
Google Scholar
4.
Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front. Neurol. 13, 886625 (2022).
PubMed
Google Scholar
5.
Myasthenia Gravis Foundation of America. Clinical overview of MG. https://myasthenia.org/Professionals/Clinical-Overview-of-MG (2023).
Google Scholar
6.
Narayanaswami P, Sanders DB, Wolfe G et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3), 114–122 (2021).
PubMed
Google Scholar
7.
Sanders DB, Wolfe GI, Benatar M et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4), 419–425 (2016).
PubMed
Google Scholar
8.
Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol. Clin. 36(2), 311–337 (2018).
PubMed
Google Scholar
9.
Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front. Neurol. 11, 538 (2020).
PubMed
Google Scholar
10.
Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev. Clin. Immunol. 18(7), 691–701 (2022).
PubMed
Google Scholar
11.
Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther. Adv. Neurol. Disord. 11, 1756285617749134 (2018).
Google Scholar
13.
Sieb JP. Myasthenia gravis: an update for the clinician. Clin. Exp. Immunol. 175(3), 408–418 (2014).
PubMed
Google Scholar
14.
Howard JF Jr, Utsugisawa K, Benatar M et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16(12), 976–986 (2017).
PubMed
Google Scholar
15.
Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther. Adv. Neurol. Disord. 16, 17562864221150327 (2023).
Google Scholar
•• This US retrospective claims analysis reports the high healthcare resource utilization incurred by patients with newly diagnosed MG compared with age-matched controls and identifies the early years following diagnosis as a period of particularly high healthcare burden.
16.
Ting A, Story T, Lecomte C, Estrin A, Syed S, Lee E. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. J. Neurol. Sci. 445, 120531 (2023).
PubMed
Google Scholar
•• This US retrospective claims analysis describes the high clinical burden and high healthcare resource utilization of patients with MG who initiated second-line therapy.
17.
Klaisner JK, Schweitzer K, Ally AJ. Myasthenia gravis patient payer channel distribution. https://uk.milliman.com/en-GB/insight/myasthenia-gravis-patient-payer-channel-distribution (2022).
Google Scholar
18.
Card D, Dobkin C, Maestas N. Does Medicare save lives? Q. J. Econ. 124(2), 597–636 (2009).
PubMed
Google Scholar
19.
Center on Budget Policy Priorities. Policy basics: Introduction to Medicaid. https://www.cbpp.org/research/health/introduction-to-medicaid (2020).
Google Scholar
20.
Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J. Med. Life 14(1), 7–16 (2021).
PubMed
Google Scholar
• This review highlights the global increase in the incidence and prevalence of MG within the past several decades.
21.
US Bureau of Labor Statistics. CPI for all Urban Consumers (CPI-U). https://www.bls.gov (2021).
Google Scholar
22.
Misra UK, Kalita J, Singh VK, Kumar S. A study of comorbidities in myasthenia gravis. Acta Neurol. Belg. 120(1), 59–64 (2020).
PubMed
Google Scholar
23.
Vijayan J, Menon D, Barnett C, Katzberg H, Lovblom LE, Bril V. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve 64(4), 462–466 (2021).
PubMed
Google Scholar
• This Canadian retrospective chart review describes the clinical profile of patients with late-onset MG and the impact of comorbidites on disease status and health outcomes.
24.
Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve 64(5), 538–544 (2021).
PubMed
Google Scholar
25.
Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG Patient Registry. Muscle Nerve 66(4), 411–420 (2022).
PubMed
Google Scholar
26.
Dong D, Chong MK-C, Wu Y, Kaminski H, Cutter G, Xu X et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual. Life Outcomes 18(1), 296 (2020).
PubMed
Google Scholar
27.
Abuzinadah AR, Alanazy MH, Butt NS, Barohn RJ, Dimachkie MM. Exacerbation rate in generalized myasthenia gravis and its predictors. Eur. Neurol. 84(1), 43–48 (2021).
PubMed
Google Scholar
• This retrospective chart review of a cohort of patients in the US with acetylcholine receptor antibody (AChR)-positive generalized MG estimates the incidence rate and predictors of MG exacerbations.
28.
Nicoli V, Tabano SM, Colapietro P, Maestri M, Ricciardi R, Stoccoro A et al. Preferential X chromosome inactivation as a mechanism to explain female preponderance in myasthenia gravis. Genes 13(4), 696 (2022).
PubMed
Google Scholar
29.
Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekjær H, Verschuuren JJ, Tallaksen CM. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology 87(20), 2139–2145 (2016).
PubMed
Google Scholar
30.
Leker RR, Karni A, Abramsky O. Exacerbation of myasthenia gravis during the menstrual period. J. Neurol. Sci. 156(1), 107–111 (1998).
PubMed
Google Scholar
31.
Howard JF Jr, Bril V, Vu T et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20(7), 526–536 (2021).
PubMed
Google Scholar
32.
Vu T, Meisel A, Mantegazza R et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evidence 1, EVIDoa2100066 (2022).
Google Scholar
33.
Bril V, Druzdz A, Grosskreutz J et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 22(5), 383–394 (2023).
PubMed
Google Scholar
34.
Howard JF Jr, Bresch S, Genge A et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 22(5), 395–406 (2023).
PubMed
Google Scholar
35.
Guptill JT, Sharma BK, Marano A, Soucy A, Krueger A, Sanders DB. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve 45(3), 363–366 (2012).
PubMed
Google Scholar
36.
Omorodion JO, Pines JM, Kaminski HJ. Inpatient cost analysis for treatment of myasthenia gravis. Muscle Nerve 56(6), 1114–1118 (2017).
PubMed
Google Scholar
• This cost analysis study revealed geographic differences in the US for inpatient costs associated with MG.
37.
Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmuller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics 38(7), 715–728 (2020).
PubMed
Google Scholar
•• This systematic literature review of economic costs associated with MG in eight countries highlights important regional variation in healthcare resource utlization, healthcare costs and disease management.
38.
Syed MJ, Khawaja A, Lisak RP. Are there racial differences in inpatient outcomes and treatment utilization following hospitalization for myasthenia gravis exacerbation? Neuroepidemiology 56(5), 380–388 (2022).
PubMed
Google Scholar
•• This US retrospective claims analysis of adult patients hospitalized with MG reports racial differences in health outcomes and inpatient treatment for MG.
|